Diroximel fumarate

Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF) . Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS) . Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity[1][2].

Product Specifications

CAS Number

[1577222-14-0]

Product Name Alternative

ALKS 8700; BIIB098

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Keap1-Nrf2

Type

Reference compound

Related Pathways

NF-κB

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/diroximel-fumarate.html

Purity

99.60

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : ≥ 10 mg/mL

Smiles

O=C(OCCN1C(CCC1=O)=O)/C=C/C(OC)=O

Molecular Formula

C11H13NO6

Molecular Weight

255.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Angela Wehr, et al. Relative Bioavailability of Monomethyl Fumarate after Administration of ALKS 8700 in Healthy Subjects (P1.403) . Neurology. Apr 2018.|[2]Yousuf MS, et al. Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decreases ISR activation in DRG neurons. bioRxiv [Preprint]. 2023 Dec 23:2023.12.22.572877.